EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting developmental reprogramming: hPSC insights for cancer interception

Xiaohui Xu, Xiaolei Dong, Jinyu Li, Yifei Liu, Zheng Wang

Trends in Pharmacological Sciences · 2026-08 · 47 (8) · 840-854

DOI: 10.1016/j.tips.2026.05.011 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Pharmacological Sciences, 2026-08. Verfasst von Xiaohui Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics and Cell Biology, School of Basic Medicine, Qingdao University, Qingdao, Shandong, China. Hauptthemen laut MEDLINE: Neoplasms, Pluripotent Stem Cells, Cellular Reprogramming. Die Arbeit nennt 75 Literaturangaben. Gefördert von: Taishan Scholar Foundation of Shandong Province, Shandong Province Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer is increasingly conceptualized as a disease of distorted human development, where oncogenic events trigger developmental reprogramming by subverting physiological lineage programs. Conventional cancer models often fail to capture this early transition, as they primarily reflect end-stage tumors or nonhuman biology. Human pluripotent stem cells (hPSCs) circumvent these limitations by enabling the reconstruction of oncogenic events within precisely defined human developmental trajectories. In this review, we examine emerging principles of lineage bias and differentiation arrest revealed by hPSC-derived models across brain, retinal, and myeloid malignancies, as well as hereditary cancer predispositions. Crucially, we discuss how these models reveal therapeutic windows linked to defined developmental states to reverse lineage hijacking, translating developmental insights into pharmacological strategies for early cancer interception.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsPluripotent Stem CellsCellular ReprogrammingHumansAnimalsCell Differentiation

Stichwörter der Autor:innen

cancer interceptiondevelopmental reprogrammingepigenetic alterationhuman pluripotent stem cellslineage specificationstage-specific pharmacology

Autor:innen und Institutionen

  • Department of Genetics and Cell Biology, School of Basic Medicine, Qingdao University, Qingdao, Shandong, China.
  • Department of Obstetrics and Gynecology, Pennsylvania State Health Milton S. Hershey Medical Center, Hershey, PA, USA.
  • Department of Genetics and Cell Biology, School of Basic Medicine, Qingdao University, Qingdao, Shandong, China; Department of Reproductive Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, Chi…

Förderung

  • Taishan Scholar Foundation of Shandong Province
  • Shandong Province Natural Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Xu, X., Dong, X., Li, J., Liu, Y., & Wang, Z. (2026). Targeting developmental reprogramming: hPSC insights for cancer interception. Trends in Pharmacological Sciences, 47(8), 840-854. https://doi.org/10.1016/j.tips.2026.05.011

Vancouver

Xu X, Dong X, Li J, Liu Y, Wang Z. Targeting developmental reprogramming: hPSC insights for cancer interception. Trends in Pharmacological Sciences. 2026;47(8):840-854. doi:10.1016/j.tips.2026.05.011

BibTeX
@article{Xu2026,
  author = {Xu, Xiaohui and Dong, Xiaolei and Li, Jinyu and Liu, Yifei and Wang, Zheng},
  title = {Targeting developmental reprogramming: hPSC insights for cancer interception},
  journal = {Trends in Pharmacological Sciences},
  year = {2026},
  volume = {47},
  number = {8},
  pages = {840--854},
  doi = {10.1016/j.tips.2026.05.011}
}
Kostenlos starten →